Chemical Biology-Lab:Publications: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 14: Line 14:
</div><br>
</div><br>
==2014==
==2014==
# Priyanka Ghosh, DoMin Lee, Kyung Bo Kim and Audra L. Stinchcomb, ''Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle treated skin'', '''Pharmaceutical Research''', 31, 148-159 (2014)
# Park, JE, Wu, Y., Carmony, KC, Miller, Z., Sharma, LK, Lee, DM, Kim, DY, Lee, W., and Kim, K.B., ''A FRET-Based Approach for Identification of Proteasome Catalytic Subunit Composition'', '''Molecular BioSystems''', 10, 196-200 (2014)
# Park, JE, Wu, Y., Carmony, KC, Miller, Z., Sharma, LK, Lee, DM, Kim, DY, Lee, W., and Kim, K.B., ''A FRET-Based Approach for Identification of Proteasome Catalytic Subunit Composition'', '''Molecular BioSystems''', 10, 196-200 (2014)
# Kasam, V., Lee, NR, Kim, K.B. & Zhan, C-G., ''Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening'', '''Bioorg. Med. Chem. Lett.''', 24, 3614-7 (2014)
# Kasam, V., Lee, NR, Kim, K.B. & Zhan, C-G., ''Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening'', '''Bioorg. Med. Chem. Lett.''', 24, 3614-7 (2014)
# Miller, Z., Lee W. & Kim, K. B., ''The Immunoproteasome as a Therapeutic Target for Hematological Malignancies'', '''Current Cancer Drug Targets''', in press (Mar. 2014)
# Miller, Z., Lee W. & Kim, K. B., ''The Immunoproteasome as a Therapeutic Target for Hematological Malignancies'', '''Current Cancer Drug Targets''', 14, 537-548 (2014)
# de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS, ''Structure-based design of either β1i or β5i specific inhibitors of human immunoproteasomes'', '''J Med Chem''', 57, 6197-209 (2014)
# de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS, ''Structure-based design of either β1i or β5i specific inhibitors of human immunoproteasomes'', '''J Med Chem''', 57, 6197-209 (2014)
# Carmony,KC, Sharma, LK, Lee, DM, Park, JE, Lee, W., and Kim, K.B., ''Elucidating the catalytic subunit composition of distinct proteasome subtypes: A crosslinkling approach employing bifunctional activity-based probes'', '''ChemBioChem''', in press (2014)
# Carmony,KC, Sharma, LK, Lee, DM, Park, JE, Lee, W., and Kim, K.B., ''Elucidating the catalytic subunit composition of distinct proteasome subtypes: A crosslinkling approach employing bifunctional activity-based probes'', '''ChemBioChem''', in press (2014)

Revision as of 07:47, 25 November 2014

Home        Research        Lab Members        Positions        Links        JC/Internal        Contact       


2014

  1. Priyanka Ghosh, DoMin Lee, Kyung Bo Kim and Audra L. Stinchcomb, Optimization of naltrexone diclofenac codrugs for sustained drug delivery across microneedle treated skin, Pharmaceutical Research, 31, 148-159 (2014)
  2. Park, JE, Wu, Y., Carmony, KC, Miller, Z., Sharma, LK, Lee, DM, Kim, DY, Lee, W., and Kim, K.B., A FRET-Based Approach for Identification of Proteasome Catalytic Subunit Composition, Molecular BioSystems, 10, 196-200 (2014)
  3. Kasam, V., Lee, NR, Kim, K.B. & Zhan, C-G., Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening, Bioorg. Med. Chem. Lett., 24, 3614-7 (2014)
  4. Miller, Z., Lee W. & Kim, K. B., The Immunoproteasome as a Therapeutic Target for Hematological Malignancies, Current Cancer Drug Targets, 14, 537-548 (2014)
  5. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS, Structure-based design of either β1i or β5i specific inhibitors of human immunoproteasomes, J Med Chem, 57, 6197-209 (2014)
  6. Carmony,KC, Sharma, LK, Lee, DM, Park, JE, Lee, W., and Kim, K.B., Elucidating the catalytic subunit composition of distinct proteasome subtypes: A crosslinkling approach employing bifunctional activity-based probes, ChemBioChem, in press (2014)

2013

  1. Zachary Miller, Lin Ao, Kyung Bo Kim and Wooin Lee, Inhibitors of the Immunoproteasome: Current Status and Future Directions, Pharm. Drug Design, 19 (22), 4140-51(2013)
  2. Kyung Bo Kim and Craig M Crews, From Epoxomicin to Carfilzomib: Chemistry, Biology, and Medical Outcomes, Natural Product Reports, 30, 600-604 (2013)
  3. Kimberly Cornish Carmony and Kyung Bo Kim, Activity-Based Imaging Probes of the Proteasome, Cell Biochemistry and Biophysics, 67, 91-101(2013)
  4. Ji Eun Park, Lin Ao, Zachary Miller, Kyungbo Kim, Ying Wu, Eun Ryoung Jang, Eun Young Lee, Kyung Bo Kim and Wooin Lee. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit β1i expressed in multiple types of solid cancer, Plos One, 8, e73732 (2013)

2012

  1. Carmony K & & Kim KB, Protac-induced proteolytic targeting, Methods in Molecular Biology, Human Press, vol. 832, Chap 44 (2012)
  2. Carmony KC, Lee DM, Wu Y, Lee NR, Wehenkel M, Lee J, Lei B, Zhan CG, Kim KB., A bright approach to the immunoproteasome, Bioorg. Med. Chem., 20, 607-613 (2012)
  3. Eun-Young Choi, Hyosung Lee, R.W. Cameron Dingle, Kyung Bo Kim and Hollie I Swanson, Development OF Novel CH223191-Based Antagonists of the Aryl Hydrocarbon Receptor , Mol. Pharm., 81, 3-11 (2012)
  4. Paola Bargagna-Mohan, Riya R. Paranthan, Adel Hamza, Chang-Guo Zhan, Do-Min Lee, Kyung Bo Kim, Daniel L. Lau, Cidambi Srinivasan, Keiko Nakayama, Keiichi I. Nakayama, Harald Herrmann, and Royce Mohan, A corneal anti-fibrotic switch identified in genetic and pharmacological deficiency of vimentin, J. Biol. Chem., 287, 989-1006 (2012)
  5. Atkinson SP, Collin J, Irina Neganova, George Anyfantis, Kyung Bo Kim, Lako M and Armstrong, L, A putative role for the immunoproteasome in the maintenance of pluripotency and cell cycle in human embryonic stem cells, Stem Cells, 30, 1373-1384 (2012)
  6. Marie Wehenkel, Jung-Ok Ban, Yik-Khuan Ho, Kimberly Cornish Carmony, Jin Tae Hong, and Kyung Bo Kim, A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumor growth in nude mice, British Journal of Cancer, 107, 53-62 (2012)
  7. Ao Lin, Ying Wu, Donghern Kim, Eun Ryoung Jang, Kyunghwa Kim, Do-min Lee, Kyung Bo Kim, Wooin Lee, Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib, Molecular Pharmaceutics, 9, 2197-2205 (2012)
  8. Eun Ryoung Jang, Na-Ra Lee, Songhee Han, Ying Wu, Lalit Kumar Sharma, Kimberly Cornish Carmony, James Marks, Do-Min Lee, Jung-Ok Ban, Marie Wehenkel, Jin Tae Hong, Kyung Bo Kim and Wooin Lee, Revisiting the Role of the Immunoproteasome in the Activation of the Canonical NF-kB Pathway, Molecular Biosystems, 8, 2295-2302(2012)
  9. Haiyan Sun, Choon-myung Lee, Shweta Tripathi, Kyung-Bo Kim and Edward T. Morgan, Nitric oxide-dependent CYP2B1 degradation is potentiated by a cytokine-regulated pathway and utlilizes the immunoproteasome subunit LMP2, Biochemical Journal, 445, 377-382 (2012)
  10. Lalit Kumar Sharma, Na-Ra Lee, Eun Ryoung Jang, Beilei Lei, Chang-Guo Zhan, Wooin Lee, Kyung-Bo Kim, Near-Infrared Activity-Based Fluorescent Probe for LMP7: A Chemical Proteomics Tool for Immunoproteasome in Living Cells, ChemBioChem, 13, 1899-1903(2012) (highlighted on the fronf cover of ChemBioChem)
  11. Nam Jin Lee, Dong Young Choi, Ju Kyoung Song, Yu Yeon Jung, Dae Han Kim, Tae Myung Kim, Dae Joong Kim, Sun Mi Kwon, Kyung Bo Kim, Kyung Eun Choi, Dong Cheul Moon,Youngsoo Kim, Sang Bae Han, Jin Tae Hong, Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kB and inhibition of monocyte chemoattractant protein-1 in urethane induced lung tumor model, Carcinogenesis, 33, 2520-2528(2012)
Retrieved from "https://openwetware.org/mediawiki/index.php?title=Chemical_Biology-Lab:Publications&oldid=845376"